# Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

> **NCT04134884** · PHASE1 · COMPLETED · sponsor: **Kathy Miller** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Talazoparib
- **DRUG:** ASTX727

## Key facts

- **NCT ID:** NCT04134884
- **Lead sponsor:** Kathy Miller
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-01
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-03-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134884, "Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04134884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*